Skip to main content
Log in

Current Management of Zollinger-Ellison Syndrome

  • Practical Therapeutics
  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Patients with Zollinger-Ellison syndrome require that management decisions be made to control the gastric acid hypersecretion and treatment directed at the gastrinoma itself. The advent of newer antisecretory drugs and increased knowledge of the natural history of this disease have led to major changes in the management of each of these two areas. Recent studies have demonstrated that treatment with the currently available histamine H2-receptor antagonists (cimetidine, ranitidine) with or without an anticholinergic agent will control gastric acid secretion in almost all patients. These studies have also shown that most patients require higher doses than those used routinely to treat peptic ulcer, treatment is only successful if an adequate dose of antisecretory drug is used and must be monitored by measuring gastric acid hypersecretion, and established criteria to regulate the dose must be used. Newer more potent antisecretory drugs such as famotidine or omeprazole will facilitate management of gastric hypersecretion but are not yet currently available.

Highly selective vagotomy should be considered in those patients who require high doses of Cimetidine or ranitidine. Total gastrectomy should be reserved for those patients unwilling or unable to take oral medication. Although aggressive surgery is not warranted in most patients because overall prognosis is excellent, tumour status should be assessed in all patients by imaging studies (CT scan, ultrasound, selective angiogram). Patients without metastatic disease and without the MEN-1 syndrome (multiple-endocrine-neoplasia type 1) should undergo exploratory laparotomy by a surgeon experienced in treating this disease, with studies suggesting a cure rate of approximately 20%. Recent studies demonstrate that patients with MEN-1 can only very rarely be cured by non-radical surgery and routine surgical exploration is not recommended. In patients with metastatic gastrinoma, at what point chemotherapy should be started has not been established.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Howard JM, Collen MJ, Cherner JA, McArthur KE, Maton PN, et al. Famotidine: an effective H2-antagonist for the therapy of Zollinger-Ellison syndrome (ZES). Gastroenterology 88: 1026–1033, 1985

    PubMed  CAS  Google Scholar 

  • Jensen RT, Doppman JL, Gardner JD. Gastrinoma. In Brooks et al. (Eds) The exocrine pancreas: biology, pathobiology and diseases, Raven Press, New York, pp. 727–745, 1986

    Google Scholar 

  • Jensen RT, Gardner JD, Raugman J-P, Pandol SJ, Doppman JL, Collen MJ. Zollinger-Ellison syndrome. Annals of Internal Medicine 98: 59–75, 1983

    PubMed  CAS  Google Scholar 

  • Lamers CBH, Lind T, Moberg S, Jansen J, Olbe L. Omeprazole in Zollinger-Ellison syndrome. Effects of a single dose and a long-term treatment in patients resistant to histamine H2-receptor antagonists. New England Journal of Medicine 310: 758–761, 1984

    Article  Google Scholar 

  • Malagelada J-R, Edis AJ, Adson MA, Von Heerden JA, Go VLW. Medical and surgical options in the management of patients with gastrinoma. Gastroenterology 84: 1524–1532, 1983

    PubMed  CAS  Google Scholar 

  • McArthur KE, Collen MJ, Cherner JA, Howard JM, Maton PN, et al. Omeprazole as a single daily dose is effective therapy in Zollinger-Ellison syndrome. Gastroenterology 88: 939–944, 1985

    PubMed  CAS  Google Scholar 

  • McCarthy DM, Hyman PE. Effect of isopropamide on response to oral Cimetidine in patients with Zollinger-Ellison syndrome. Digestive Diseases and Sciences 27: 353–359, 1982

    Article  PubMed  CAS  Google Scholar 

  • McCarthy DM, Peiken SR, Lopatin, RN. Hyperparathyroidism — a reversible cause of cimetidine-resistant gastric resection. British Medical Journal 1: 765–766, 1979

    Article  Google Scholar 

  • Moertel CG, Hanley JA, Johnson LA. Streptozotocin alone compared with streptozotocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. New England Journal of Medicine 303: 1189–1194, 1980

    Article  PubMed  CAS  Google Scholar 

  • Raufman J-P, Collins SM, Pandol SJ, Korman LK, Collen MJ, et al. Reliability of symptoms in assessing control of gastric acid secretion in patients with Zollinger-Ellison syndrome. Gastroenterology 84: 108–113, 1983

    PubMed  CAS  Google Scholar 

  • Richardson CT, Peters MN, Feldman M, McClelland RN, Walsh JH, et al. Treatment of Zollinger-Ellison syndrome with exploratory laparotomy, proximal gastric vagotomy and H2-receptor antagonists. Gastroenterology 89: 357–367, 1985

    PubMed  CAS  Google Scholar 

  • Thompson JD, Lewis BG, Wiener I, Townsend Jr CM. The role of surgery in the Zollinger-Ellison syndrome. Annals of Surgery 197: 594–607, 1983

    Article  PubMed  CAS  Google Scholar 

  • Zollinger RM, Ellison EH. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Annals of Surgery 142: 709–723, 1955

    Article  PubMed  CAS  Google Scholar 

  • Zollinger RM, Ellison EC, Fabri PJ, Johnson J, Sparks J, Carey LC. Primary peptic ulcerations of the jejunum associated with islet cell tumors: twenty-five-year appraisal. Annals of Surgery 192: 422–430, 1980

    Article  PubMed  CAS  Google Scholar 

  • Zollinger RM, Martin EW, Carey LC, Sparks J, Minton JP. Observations on the postoperative tumor growth behavior of certain islet cell tumors. Annals of Surgery 184: 525–530, 1976

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jensen, R.T., Maton, P.N. & Gardner, J.D. Current Management of Zollinger-Ellison Syndrome. Drugs 32, 188–196 (1986). https://doi.org/10.2165/00003495-198632020-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-198632020-00006

Keywords

Navigation